Literature DB >> 1263092

Intestinal secretion of erythromycin base.

D R Holland, J F Quay.   

Abstract

Erythromycin fluxes into rabbit midjejunal segments were studied. When erythromycin was infused into the jugular vein of anesthetized rabbits, the antibiotic was secreted into the segments at a rate of 0.0136 +/- 0.0023 mg/min. Preloading of the segments with five and 20 times the plasma concentration did not diminish this secretion. Protein binding of the antibiotic within the lumen could not explain this secretion, since both ultrafiltration and chromatography of luminal solutions indicated that the biological activity was free erythromycin. Moreover, the transmural potential across the intestinal mucosa is likely to be theprincipal driving force, since greater than 80 mv would be required to sustain the observed secretion against an imposed 20-fold concentration difference between blood and lumen. The best explanation for the intestinal secretion of erythromycin appears to be an active transport pathway capable of concentrating erythromycin in the lumen. It is not clear what endogenous substances are transported by this pathway.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1263092     DOI: 10.1002/jps.2600650325

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  11 in total

1.  Linear pharmacokinetic models and vanishing exponential terms: implications in pharmacokinetics.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1976-10

2.  Excretion of ciprofloxacin into the large bowel of the rabbit.

Authors:  J Ramon; S Dautrey; R Farinoti; C Carbon; E Rubinstein
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

3.  Intestinal elimination of ciprofloxacin in rabbits.

Authors:  J Ramon; S Dautrey; R Farinoti; C Carbon; E Rubinstein
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

4.  Role of intestinal excretion in the effect of subcutaneously administered sedecamycin on cecal infection caused by Treponema hyodysenteriae in mice.

Authors:  T Hayashi; J Okada; S Kondo; T Yamazaki
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

5.  Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man.

Authors:  P B Watkins; S A Wrighton; E G Schuetz; D T Molowa; P S Guzelian
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

6.  Dose-related pharmacokinetics after oral administration of a new formulation of erythromycin base.

Authors:  K Josefsson; T Bergan; L Magni
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

7.  Intersubject and dose-related variability after intravenous administration of erythromycin.

Authors:  K L Austin; L E Mather; C R Philpot; P J McDonald
Journal:  Br J Clin Pharmacol       Date:  1980-09       Impact factor: 4.335

8.  Tissue distribution and excretion of radioactively labelled compounds in the Wistar rat after administration of [N-methyl-14C]-erythromycin A.

Authors:  I O Kibwage; M Michiels; R Hendriks; T Cachet; A Verbruggen; J Hoogmartens; H Vanderhaeghe
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Jan-Mar       Impact factor: 2.441

Review 9.  Adverse effects of macrolide antibacterials.

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Drug Saf       Date:  1993-11       Impact factor: 5.606

10.  Site-dependent small intestinal absorption of ranitidine.

Authors:  T Gramatté; E el Desoky; U Klotz
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.